Market Size of Liver Fluke Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Liver Fluke Treatment Market Analysis
The liver fluke treatment market is expected to register a CAGR of 4.2% during the forecast period.
The COVID-19 outbreak had a significant impact on the market. Due to the temporary shutdown of production facilities, export restrictions, increased demand for COVID-19 medication, disruptions in the supply of goods, and interruptions in services, the impact of the outbreak in its initial phase on the liver fluke drugs market was substantial. Additionally, clinical trials of the drug were reduced as more and more companies delayed the start of many new courses in several countries.
In addition, the COVID-19 pandemic has seen a decline in outpatient services for patients with infectious diseases, which also impacted the market growth. For instance, as per the article published by NCMI in September 2021, the COVID-19 pandemic affected liver fluke infection prevention, testing, treatment, and vaccination services globally. Similarly, as per the data published by the WHO, in 2020, most malaria-endemic countries faced moderate disruptions in anti-parasitic service delivery. As a result of the resumed services and procedures, the liver fluke treatment market is recovering from the effect of COVID-19, and it is expected to regain its full potential during the forecast period.
The increasing cases of liver fluke in cattle, sheep, and humans are propelling the growth of the market. As per the study published by NCBI in December 2021, the prevalence of fascioliasis in cattle was found to be 90.13% in 2021. In addition, as per another study published by NCBI in July 2022, the prevalence of Fasciola spp infection in livestock ranged from 9.1% to 37.67% in the Eastern Cape province of South Africa in the last six decades (1960-2021). Additionally, according to data released by the CDC in September 2021, the number of infected people was expected to exceed two million worldwide in 2021.
Increasing cases of liver fluke infection in humans and animals and growing awareness of liver fluke infections among the population are the key driving factors for liver fluke treatment market growth. However, the requirement for long treatment cycles for liver fluke infection is likely to hamper the growth of the market.
Liver Fluke Treatment Industry Segmentation
Liver flukes are parasites that can cause diseases in humans and some animals.
The liver fluke treatment market is segmented by drug type (albendazole, praziquantel, triclabendazole, nitazoxanide, and other drugs), application (human and animals), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.
| By Drug Type | |
| Albendazole | |
| Praziquantel | |
| Triclabendazole | |
| Nitazoxanide | |
| Other Drugs |
| By Application | |
| Human | |
| Animals |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Liver Fluke Treatment Market Size Summary
The liver fluke treatment market is poised for growth, driven by the increasing prevalence of liver fluke infections in both humans and animals. The market experienced significant disruptions due to the COVID-19 pandemic, which led to temporary shutdowns of production facilities, export restrictions, and a shift in focus towards COVID-19 medications. These factors resulted in delays in clinical trials and a decline in outpatient services for infectious diseases, impacting the market's initial growth trajectory. However, as services and procedures have resumed, the market is recovering and is expected to regain its full potential. The rising awareness of liver fluke infections and the demand for effective treatment solutions are key factors propelling market growth, despite the challenges posed by long treatment cycles.
Triclabendazole, a benzimidazole compound, is a cornerstone in the treatment of fascioliasis and is recognized as a first-line therapy by the CDC and WHO. Its effectiveness and relatively mild side effects have contributed to its widespread use, boosting market growth. The North American region is anticipated to hold a significant share of the market, driven by the high prevalence of Fasciola hepatica infections in cattle and sheep. The competitive landscape features major players like Novartis AG, GlaxoSmithKline PLC, and Zoetis Inc., who are actively developing and launching new therapeutic drugs to meet the growing demand. Recent drug approvals and innovations in treatment options are expected to further propel market expansion in North America and beyond.
Liver Fluke Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Incidence of Infection in Humans and Cattles
-
1.2.2 Increasing Research and Development for Liver Fluke Treatment
-
-
1.3 Market Restraints
-
1.3.1 Requirement of Long Treatment Cycles for Liver Fluke Infection
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Drug Type
-
2.1.1 Albendazole
-
2.1.2 Praziquantel
-
2.1.3 Triclabendazole
-
2.1.4 Nitazoxanide
-
2.1.5 Other Drugs
-
-
2.2 By Application
-
2.2.1 Human
-
2.2.2 Animals
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Liver Fluke Treatment Market Size FAQs
What is the current Liver Fluke Treatment Market size?
The Liver Fluke Treatment Market is projected to register a CAGR of 4.20% during the forecast period (2024-2029)
Who are the key players in Liver Fluke Treatment Market?
Romark Laboratories, L.C. , Zoetis Inc., Elanco , GlaxoSmithKline PLC and Endo International PLC (Par Pharmaceutical) are the major companies operating in the Liver Fluke Treatment Market.
